Summary of opinion: Stelara, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Stelara, 27/02/2025 Positive
Summary of opinion: Imfinzi, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Imfinzi, 27/02/2025 Positive
Summary of opinion: Kaftrio, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Kaftrio, 27/02/2025 Positive
Combination of cystic fibrosis medicines to treat patients with rare mutations
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Combination of cystic fibrosis medicines to treat patients with rare mutations
Summary of opinion: Columvi, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Columvi, 27/02/2025 Positive
Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Opinion
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Opinion
Summary of opinion: Keytruda, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Keytruda, 27/02/2025 Positive
Summary of opinion: Kalydeco, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Kalydeco, 27/02/2025 Positive
List of centrally authorised products with safety-related changes to the product information
Submitted by Anonymous (not verified) on 28 February 2025 - 9:56
List of centrally authorised products with safety-related changes to the product information
Procedural advice on CHMP/CAT/PRAC Rapporteur/Co-Rapporteur appointment principles, objective criteria and methodology in accordance with Article 62 (1) of Regulation (EC) No 726/2004
Submitted by Anonymous (not verified) on 28 February 2025 - 9:53
Procedural advice on CHMP/CAT/PRAC Rapporteur/Co-Rapporteur appointment principles, objective criteria and methodology in accordance with Article 62 (1) of Regulation (EC) No 726/2004